{"id":391600,"date":"2014-07-14T00:00:00","date_gmt":"2014-07-14T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforeu0914-biopharma-asthma-what-are-the-expectations-for-optimal-positioning-of-new-and-emerging-inhaled-and-biological\/"},"modified":"2026-04-22T05:28:33","modified_gmt":"2026-04-22T05:28:33","slug":"pforeu0914-biopharma-asthma-what-are-the-expectations-for-optimal-positioning-of-new-and-emerging-inhaled-and-biological","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/pforeu0914-biopharma-asthma-what-are-the-expectations-for-optimal-positioning-of-new-and-emerging-inhaled-and-biological\/","title":{"rendered":"Asthma (What Are the Expectations for Optimal Positioning of New and Emerging Inhaled and Biological Therapies in Market Access Systems?) | Physician &#038; Payer Forum | EU5 | 2014"},"content":{"rendered":"<p>High unmet need exists for severe, refractory asthma patients, for whom Genentech\/Novartis\u2019s Xolair is currently the only therapeutic option. Together with a number of newly approved agents for the wider asthma population, including GlaxoSmithKline\/Theravance\u2019s Relvar, and the anticipated approval of Boehringer Ingelheim\/Pfizer\u2019s Spiriva, novel brands seeking to address such need are likely to drive market growth despite increasing generic and branded-generic erosion of current key players. Specifically, interleukin-5 (IL-5)-targeting biologics in Phase III clinical development\u2014Cephalon\/Teva\u2019s Cinquil, GSK\u2019s Bosatria and MedImmune\/AstraZeneca\/BioWa\u2019s benralizumab\u2014will infuse a competitive dynamic to the severe, disease-refractory market segment in asthma. However, the entry of expensive biologics into the asthma market will be met with increasing reimbursement restrictions and other market access challenges owing to payers\u2019 heightened cost-consciousness in the current economic climate across the EU5 countries under study.<\/p>\n","protected":false},"template":"","class_list":["post-391600","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-asthma","biopharma-date-574"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391600","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391600\/revisions"}],"predecessor-version":[{"id":577017,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391600\/revisions\/577017"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391600"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}